Article Information
History
- October 23, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jessica R. Koski1,2,
- Laura Langohr3,2,1,4,*,
- Tuulia Räisänen1,2,*,
- Atte K. Lahtinen1,2,
- Marja Hakkarainen1,2,5,
- Caroline A. Heckman3,4,
- Ulla Wartiovaara-Kautto1,2,5,**,#,
- Esa Pitkänen3,1,4,**,# and
- Outi Kilpivaara1,2,4,6,7,**,#
- 1Applied Tumor Genomics, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- 2Department of Medical and Clinical Genetics, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- 3Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
- 4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
- 5Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
- 6HUSLAB Laboratory of Genetics, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland
- 7K. Albin Johansson Cancer Research Fellow, Foundation for the Finnish Cancer Institute, Helsinki, Finland
- ↵#Correspondence to Outi Kilpivaara (outi.kilpivaara{at}helsinki.fi), Esa Pitkänen (esa.pitkanen{at}helsinki.fi), and Ulla Wartiovaara-Kautto (ulla.wartiovaara-kautto{at}hus.fi)
Posted October 23, 2024.
Pathogenicity evaluation of coding germline variants identifies rare alleles enriched in hematological patients of a founder population
